6200 LOOKOUT ROAD, BOULDER, CO
Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
Enliven Therapeutics Increases Authorized Shares to 200 Million
Reports First Quarter Financial Results and Provides a Business Update
Annual Report to Security Holders
Financial Results, Press Release
Bolsters Board to Prepare for Next Phase of Development
Announces New CEO to Drive Next Phase of Development
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Registration Statement for Additional Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload